Clinical Trials Logo

Hepatitis D clinical trials

View clinical trials related to Hepatitis D.

Filter by:

NCT ID: NCT00117533 Recruiting - Chronic Hepatitis B Clinical Trials

Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta

Start date: September 2005
Phase: Phase 4
Study type: Interventional

The treatment of choice for chronic hepatitis D is uncertain. The investigators hypothesize that pegylated interferon (IFN) alfa-2b in combination with ribavirin (RBV) may be effective in the treatment of chronic hepatitis D patients who are also infected by hepatitis B virus (HBV). The purpose of this study is to test this hypothesis. The investigators will use pegylated IFN alfa-2b in combination with RBV for the treatment of patients with dual chronic hepatitis D virus (HDV) and HBV infection. A 24-week course of combination therapy pegylated IFN+RBV will be used.

NCT ID: NCT00001971 Recruiting - Hepatitis C Clinical Trials

Evaluation of Patients With Liver Disease

Start date: May 27, 1992
Phase:
Study type: Observational

The proposed study aims to evaluate, investigate, and follow-up patients suffering from acute and chronic liver disease. The study will focus on understanding diseases affecting the liver. Patients participating in the study will first undergo a routine check-up as an outpatient. They will be asked to provide blood and urine samples for laboratory testing and will undergo an ultrasound of the liver. Ultrasound examinations use sound waves to determine the size and texture of the liver. After the initial visit subjects will be requested to follow-up once a year at the outpatient department for a similar check-up. Additional tests may be requested throughout the study to provide information for other research studies and individual consent will be requested. These tests may include liver biopsies, skin biopsies, and / or specialized blood, plasma, and lymphocyte examinations. Subjects that qualify for medications presently being studied may be offered the opportunity to benefit from experimental therapy.